N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more
N4 Pharma PLC (N4P) - Net Assets
Latest net assets as of June 2025: GBX1.77 Million GBX
Based on the latest financial reports, N4 Pharma PLC (N4P) has net assets worth GBX1.77 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.85 Million) and total liabilities (GBX78.37K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.77 Million |
| % of Total Assets | 95.75% |
| Annual Growth Rate | -6.09% |
| 5-Year Change | -82.19% |
| 10-Year Change | 1.62% |
| Growth Volatility | 89.81 |
N4 Pharma PLC - Net Assets Trend (1985–2024)
This chart illustrates how N4 Pharma PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for N4 Pharma PLC (1985–2024)
The table below shows the annual net assets of N4 Pharma PLC from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX651.40K | -45.43% |
| 2023-12-31 | GBX1.19 Million | -42.84% |
| 2022-12-31 | GBX2.09 Million | -1.95% |
| 2021-12-31 | GBX2.13 Million | -41.77% |
| 2020-12-31 | GBX3.66 Million | +270.42% |
| 2019-12-31 | GBX987.34K | +12.20% |
| 2018-12-31 | GBX879.94K | -31.24% |
| 2017-12-31 | GBX1.28 Million | +22.94% |
| 2016-12-31 | GBX1.04 Million | +62.40% |
| 2015-12-31 | GBX641.00K | -38.48% |
| 2014-12-31 | GBX1.04 Million | -69.81% |
| 2013-12-31 | GBX3.45 Million | -4.24% |
| 2012-12-31 | GBX3.60 Million | +3.30% |
| 2011-12-31 | GBX3.49 Million | +18.03% |
| 2010-12-31 | GBX2.96 Million | +12.56% |
| 2009-12-31 | GBX2.63 Million | +83.96% |
| 2008-12-31 | GBX1.43 Million | +22.26% |
| 2007-12-31 | GBX1.17 Million | +29.35% |
| 2006-12-31 | GBX903.00K | +132.73% |
| 2005-12-31 | GBX388.00K | -53.59% |
| 2004-12-31 | GBX836.00K | +205.96% |
| 2003-12-31 | GBX-789.00K | +15.61% |
| 2002-12-31 | GBX-935.00K | +19.95% |
| 2001-12-31 | GBX-1.17 Million | +70.72% |
| 2000-12-31 | GBX-3.99 Million | -25.64% |
| 1999-12-31 | GBX-3.17 Million | -15.12% |
| 1998-12-31 | GBX-2.76 Million | -367.77% |
| 1997-12-31 | GBX1.03 Million | -90.58% |
| 1996-12-31 | GBX10.93 Million | -10.49% |
| 1995-12-31 | GBX12.21 Million | +16.55% |
| 1994-12-31 | GBX10.48 Million | +26.77% |
| 1993-12-31 | GBX8.26 Million | +17.54% |
| 1992-12-31 | GBX7.03 Million | -24.63% |
| 1991-12-31 | GBX9.33 Million | -3.28% |
| 1990-12-31 | GBX9.64 Million | -13.02% |
| 1989-12-31 | GBX11.09 Million | +21.40% |
| 1988-12-31 | GBX9.13 Million | +7.84% |
| 1987-12-31 | GBX8.47 Million | +6.84% |
| 1986-12-31 | GBX7.93 Million | +5.12% |
| 1985-12-31 | GBX7.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to N4 Pharma PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 642.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX1.58 Million | 243.82% |
| Other Comprehensive Income | GBX114.78K | 17.72% |
| Other Components | GBX9.35 Million | 1444.11% |
| Total Equity | GBX647.65K | 100.00% |
N4 Pharma PLC Competitors by Market Cap
The table below lists competitors of N4 Pharma PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
City Of London Investment Trust
LSE:CTY
|
$633.30 |
|
Critical Reagent Processing Corp.
PINK:GRXXD
|
$633.73 |
|
ENRTD
OTCQB:ENRTD
|
$634.69 |
|
SABIEN TECH GRP
BE:SUJ
|
$636.62 |
|
BlackRock Greater Europe Investment Trust plc
LSE:BRGE
|
$632.70 |
|
Sonic Foundry Inc
PINK:SOFO
|
$631.34 |
|
Shang Properties Inc
PSE:SHNG
|
$631.29 |
|
COME SURE GROUP
BE:0CS
|
$630.47 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in N4 Pharma PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,127,636 to 647,647, a change of -479,989 (-42.6%).
- Net loss of 1,059,000 reduced equity.
- New share issuances of 630,000 increased equity.
- Other comprehensive income increased equity by 7,390.
- Other factors decreased equity by 58,379.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.06 Million | -163.52% |
| Share Issuances | GBX630.00K | +97.28% |
| Other Comprehensive Income | GBX7.39K | +1.14% |
| Other Changes | GBX-58.38K | -9.01% |
| Total Change | GBX- | -42.57% |
Book Value vs Market Value Analysis
This analysis compares N4 Pharma PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 250.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.04x to 250.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | GBX11.11 | GBX0.48 | x |
| 1986-12-31 | GBX11.68 | GBX0.48 | x |
| 1987-12-31 | GBX12.47 | GBX0.48 | x |
| 1988-12-31 | GBX13.45 | GBX0.48 | x |
| 1989-12-31 | GBX16.33 | GBX0.48 | x |
| 1990-12-31 | GBX13.91 | GBX0.48 | x |
| 1991-12-31 | GBX7.61 | GBX0.48 | x |
| 1992-12-31 | GBX4.42 | GBX0.48 | x |
| 1993-12-31 | GBX5.19 | GBX0.48 | x |
| 1994-12-31 | GBX6.51 | GBX0.48 | x |
| 1995-12-31 | GBX6.63 | GBX0.48 | x |
| 1996-12-31 | GBX5.67 | GBX0.48 | x |
| 1997-12-31 | GBX0.52 | GBX0.48 | x |
| 1998-12-31 | GBX-1.08 | GBX0.48 | x |
| 1999-12-31 | GBX-0.71 | GBX0.48 | x |
| 2000-12-31 | GBX-0.83 | GBX0.48 | x |
| 2001-12-31 | GBX-1.39 | GBX0.48 | x |
| 2002-12-31 | GBX-0.19 | GBX0.48 | x |
| 2003-12-31 | GBX-0.16 | GBX0.48 | x |
| 2004-12-31 | GBX0.15 | GBX0.48 | x |
| 2005-12-31 | GBX0.08 | GBX0.48 | x |
| 2006-12-31 | GBX0.18 | GBX0.48 | x |
| 2007-12-31 | GBX0.23 | GBX0.48 | x |
| 2008-12-31 | GBX0.28 | GBX0.48 | x |
| 2009-12-31 | GBX0.51 | GBX0.48 | x |
| 2010-12-31 | GBX0.43 | GBX0.48 | x |
| 2011-12-31 | GBX0.50 | GBX0.48 | x |
| 2012-12-31 | GBX0.52 | GBX0.48 | x |
| 2013-12-31 | GBX0.53 | GBX0.48 | x |
| 2014-12-31 | GBX0.15 | GBX0.48 | x |
| 2015-12-31 | GBX0.06 | GBX0.48 | x |
| 2016-12-31 | GBX0.03 | GBX0.48 | x |
| 2017-12-31 | GBX0.02 | GBX0.48 | x |
| 2018-12-31 | GBX0.01 | GBX0.48 | x |
| 2019-12-31 | GBX0.01 | GBX0.48 | x |
| 2020-12-31 | GBX0.03 | GBX0.48 | x |
| 2021-12-31 | GBX0.01 | GBX0.48 | x |
| 2022-12-31 | GBX0.01 | GBX0.48 | x |
| 2023-12-31 | GBX0.00 | GBX0.48 | x |
| 2024-12-31 | GBX0.00 | GBX0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently N4 Pharma PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -163.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14542.71%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.20x
- Recent ROE (-163.52%) is below the historical average (-59.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 9.68% | 3.52% | 1.58x | 1.74x | GBX-24.20K |
| 1986 | 9.16% | 3.82% | 1.51x | 1.59x | GBX-66.80K |
| 1987 | 11.20% | 4.47% | 1.46x | 1.72x | GBX102.00K |
| 1988 | 12.46% | 4.27% | 1.63x | 1.78x | GBX224.60K |
| 1989 | 7.65% | 2.64% | 1.76x | 1.65x | GBX-260.90K |
| 1990 | -17.87% | -7.35% | 1.48x | 1.64x | GBX-2.69 Million |
| 1991 | -27.95% | -7.07% | 1.25x | 3.15x | GBX-3.54 Million |
| 1992 | -30.34% | -4.28% | 1.98x | 3.59x | GBX-2.84 Million |
| 1993 | 15.82% | 3.72% | 1.72x | 2.47x | GBX480.60K |
| 1994 | 18.73% | 4.44% | 1.50x | 2.80x | GBX914.40K |
| 1995 | 18.96% | 4.21% | 1.47x | 3.06x | GBX1.09 Million |
| 1996 | 1.46% | 0.25% | 1.89x | 3.16x | GBX-932.90K |
| 1997 | -1263.11% | -33.71% | 1.42x | 26.41x | GBX-13.11 Million |
| 1998 | 0.00% | -34.38% | 1.97x | 0.00x | GBX-4.69 Million |
| 1999 | 0.00% | -6.24% | 2.26x | 0.00x | GBX-465.50K |
| 2000 | 0.00% | -11.26% | 1.72x | 0.00x | GBX-384.10K |
| 2001 | 0.00% | 13.12% | 1.09x | 0.00x | GBX1.24 Million |
| 2002 | 0.00% | 9.92% | 0.52x | 0.00x | GBX294.50K |
| 2003 | 0.00% | 9.55% | 0.45x | 0.00x | GBX247.90K |
| 2004 | 36.03% | 17.18% | 0.34x | 6.20x | GBX205.90K |
| 2005 | -103.09% | -37.24% | 0.25x | 10.97x | GBX-438.80K |
| 2006 | 57.03% | 36.84% | 0.99x | 1.56x | GBX424.70K |
| 2007 | 22.69% | 16.94% | 0.92x | 1.45x | GBX148.20K |
| 2008 | 18.21% | 13.15% | 1.00x | 1.39x | GBX117.20K |
| 2009 | 8.15% | 11.46% | 0.49x | 1.44x | GBX-48.70K |
| 2010 | 12.31% | 18.97% | 0.48x | 1.35x | GBX68.30K |
| 2011 | 14.81% | 17.41% | 0.60x | 1.42x | GBX168.00K |
| 2012 | 3.77% | 5.08% | 0.55x | 1.34x | GBX-224.50K |
| 2013 | -4.52% | -6.90% | 0.52x | 1.26x | GBX-501.20K |
| 2014 | -229.75% | -175.51% | 0.74x | 1.77x | GBX-2.50 Million |
| 2015 | -164.27% | 0.00% | 0.00x | 1.03x | GBX-1.12 Million |
| 2016 | -2.11% | -1.90% | 1.03x | 1.07x | GBX-126.10K |
| 2017 | -143.54% | -1671.35% | 0.08x | 1.14x | GBX-1.96 Million |
| 2018 | -134.67% | -1627.03% | 0.07x | 1.22x | GBX-1.27 Million |
| 2019 | -88.76% | 0.00% | 0.00x | 1.08x | GBX-975.11K |
| 2020 | -35.68% | 0.00% | 0.00x | 1.05x | GBX-1.67 Million |
| 2021 | -72.52% | 0.00% | 0.00x | 1.10x | GBX-1.76 Million |
| 2022 | -49.29% | 0.00% | 0.00x | 1.04x | GBX-1.24 Million |
| 2023 | -112.54% | -64976.96% | 0.00x | 1.13x | GBX-1.38 Million |
| 2024 | -163.52% | -14542.71% | 0.01x | 1.20x | GBX-1.12 Million |
Industry Comparison
This section compares N4 Pharma PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,140,692,388
- Average return on equity (ROE) among peers: 3.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| N4 Pharma PLC (N4P) | GBX1.77 Million | 9.68% | 0.04x | $632.90 |
| Animalcare Group Plc (ANCR) | $78.80 Million | -0.10% | 0.40x | $23.67K |
| Alliance Pharma plc (APH) | $16.63 Million | 24.70% | 2.42x | $42.55K |
| Beximco Pharmaceuticals Limited (BXP) | $32.80 Billion | 10.72% | 0.53x | $31.61K |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $1.12K |
| Eco Animal Health Group Plc (EAH) | $9.77 Million | 20.11% | 0.69x | $8.46K |
| Hellenic Dynamics PLC (HELD) | $-102.20K | 0.00% | 0.00x | $1.10 |
| Indivior PLC (INDV) | $209.00 Million | 64.11% | 6.90x | $187.94K |
| Provexis plc (PXS) | $7.58 Million | -15.68% | 0.05x | $3.45K |